Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals shows a slight decrease today, losing -€0.500 (-0.670%) compared to yesterday.
The stock is an absolute favorite of our community with 41 Buy predictions and no Sell predictions.
With a target price of 109 € there is a positive potential of 47.3% for Rhythm Pharmaceuticals compared to the current price of 74.0 €.
Our community identified positive and negative aspects for Rhythm Pharmaceuticals stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Rhythm Pharmaceuticals stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -0.670% | 0.685% | -3.922% | 41.346% | -21.390% | 332.353% | 350.920% |
| Heron Therapeutics Inc. | 1.880% | 12.739% | 1.659% | -50.864% | -28.501% | -67.883% | -94.618% |
| Evolus Inc | -0.520% | 7.961% | -10.945% | -55.318% | -29.083% | -48.467% | -57.056% |
| Sangamo Therapeutics Inc. | 0.090% | 1.388% | -29.790% | -61.259% | -33.162% | -84.467% | -97.559% |
Comments
Rhythm Pharmaceuticals (RYTM) had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat